Large-scale trial results indicate that Novo Nordisk's weight loss drug Ozempic is associated with rare visual loss, supporting earlier research findings from Harvard University this year. Obese patients using Ozempic are more than twice as likely to be diagnosed with NAION. NAION occurs when reduced blood flow damages the visual nerve. The risk of this eye condition remains low; patients should be vigilant. Novo Nordisk's stock price in Denmark once fell over 3.3%.
Risk Warning and Disclaimer
The market carries risks, and investments should be made cautiously. This article does not constitute personal investment advice and does not take into account the specific investment goals, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article align with their specific circumstances. Investment based on this is at one's own risk

Recent research indicates that Novo Nordisk's weight loss drug Ozempic is associated with rare visual loss (NAION), with obese patients using the drug being diagnosed with NAION at more than twice the rate. Although the risk of the eye condition remains relatively low, patients should remain vigilant. Novo Nordisk's stock price once fell by more than 3.3%

- Large-scale trial results indicate that Novo Nordisk's weight loss drug Ozempic is associated with rare visual loss, supporting earlier research from Harvard University.  
- Obese patients using Ozempic have more than double the likelihood of being diagnosed with NAION, a condition caused by reduced blood flow damaging the visual nerve.  
- Although the risk of this eye condition remains low, patients should be vigilant; Novo Nordisk's stock price fell over 3.3% following the news.

Wallstreetcn